Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors

Lu Ting Kuo, Kuang Ting Kuo, Ming Jang Lee, Chih Chun Wei, Francesco Scaravilli, Jui Chang Tsai, Ham Min Tseng, Meng Fai Kuo, Yong Kwang Tu

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Recent studies have revealed a correlation between specific genetic changes, such as loss of chromosome 1p and 19q, and sensitivity of oligodendroglial neoplasm to radiotherapy and chemotherapy; epigenetic changes also play an important role in some tumors. In this retrospective study, we analyzed chromosomal alterations in 17 loci and promoter methylation status of 8 tumor-related genes in 49 oligodendroglial tumors (29 WHO grade II and 11 WHO grade III oligodendrogliomas; 7 WHO grade II and 2 WHO grade III oligoastrocytomas) using quantitative microsatellite analysis and methylation-specific polymerase chain reaction and correlated this information with clinical data. We also performed immunohistochemical stains for Ki-67 and O (6)-methyl guanine-DNA methyl transferase. Our results showed that the frequency of deletions in regions on 1p, 9p, 10q, 17p and 19q were 71.4%, 26.5%, 6.1%, 69.4% and 89.8%, respectively. Promoter methylation was detected in p14, p15, p16, p53, p73, PTEN, MGMT and RASSF1A genes in 24.5%, 6.1%, 46.9%, 0%, 6.1%, 42.9%, 53.1% and 77.6% of tumors, respectively. Statistical analysis identified that 9p22 loss, p73 methylation and p15 methylation were independently associated with reduced overall survival, and Ki-67 labeling index (LI) ≥ 5%, 9p22 loss, no loss of 19q, p73 methylation, p14 methylation and unmethylated MGMT predicted shorter progression-free survival. Our findings suggest that the frequent deletion and hypermethylation of tumor-related genes may represent a mechanism of tumor development and progression and emphasize the importance of defining new molecular markers for predicting prognosis, tumor recurrence and therapeutic response in cancer management.

Original languageEnglish
Pages (from-to)2872-2879
Number of pages8
JournalInternational Journal of Cancer
Volume124
Issue number12
DOIs
Publication statusPublished - Jun 15 2009
Externally publishedYes

Fingerprint

Epigenomics
Methylation
Pathology
Neoplasms
Genes
Oligodendroglioma
Guanine
Transferases
Microsatellite Repeats
Disease-Free Survival
Coloring Agents
Radiotherapy
Retrospective Studies
Chromosomes
Recurrence
Drug Therapy
Polymerase Chain Reaction
DNA

Keywords

  • Epigenetic
  • Genetic
  • Glioma
  • Oligodendroglial tumors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. / Kuo, Lu Ting; Kuo, Kuang Ting; Lee, Ming Jang; Wei, Chih Chun; Scaravilli, Francesco; Tsai, Jui Chang; Tseng, Ham Min; Kuo, Meng Fai; Tu, Yong Kwang.

In: International Journal of Cancer, Vol. 124, No. 12, 15.06.2009, p. 2872-2879.

Research output: Contribution to journalArticle

Kuo, LT, Kuo, KT, Lee, MJ, Wei, CC, Scaravilli, F, Tsai, JC, Tseng, HM, Kuo, MF & Tu, YK 2009, 'Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors', International Journal of Cancer, vol. 124, no. 12, pp. 2872-2879. https://doi.org/10.1002/ijc.24303
Kuo, Lu Ting ; Kuo, Kuang Ting ; Lee, Ming Jang ; Wei, Chih Chun ; Scaravilli, Francesco ; Tsai, Jui Chang ; Tseng, Ham Min ; Kuo, Meng Fai ; Tu, Yong Kwang. / Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. In: International Journal of Cancer. 2009 ; Vol. 124, No. 12. pp. 2872-2879.
@article{339f11cfeb0148eea6ce69c99c02a792,
title = "Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors",
abstract = "Recent studies have revealed a correlation between specific genetic changes, such as loss of chromosome 1p and 19q, and sensitivity of oligodendroglial neoplasm to radiotherapy and chemotherapy; epigenetic changes also play an important role in some tumors. In this retrospective study, we analyzed chromosomal alterations in 17 loci and promoter methylation status of 8 tumor-related genes in 49 oligodendroglial tumors (29 WHO grade II and 11 WHO grade III oligodendrogliomas; 7 WHO grade II and 2 WHO grade III oligoastrocytomas) using quantitative microsatellite analysis and methylation-specific polymerase chain reaction and correlated this information with clinical data. We also performed immunohistochemical stains for Ki-67 and O (6)-methyl guanine-DNA methyl transferase. Our results showed that the frequency of deletions in regions on 1p, 9p, 10q, 17p and 19q were 71.4{\%}, 26.5{\%}, 6.1{\%}, 69.4{\%} and 89.8{\%}, respectively. Promoter methylation was detected in p14, p15, p16, p53, p73, PTEN, MGMT and RASSF1A genes in 24.5{\%}, 6.1{\%}, 46.9{\%}, 0{\%}, 6.1{\%}, 42.9{\%}, 53.1{\%} and 77.6{\%} of tumors, respectively. Statistical analysis identified that 9p22 loss, p73 methylation and p15 methylation were independently associated with reduced overall survival, and Ki-67 labeling index (LI) ≥ 5{\%}, 9p22 loss, no loss of 19q, p73 methylation, p14 methylation and unmethylated MGMT predicted shorter progression-free survival. Our findings suggest that the frequent deletion and hypermethylation of tumor-related genes may represent a mechanism of tumor development and progression and emphasize the importance of defining new molecular markers for predicting prognosis, tumor recurrence and therapeutic response in cancer management.",
keywords = "Epigenetic, Genetic, Glioma, Oligodendroglial tumors",
author = "Kuo, {Lu Ting} and Kuo, {Kuang Ting} and Lee, {Ming Jang} and Wei, {Chih Chun} and Francesco Scaravilli and Tsai, {Jui Chang} and Tseng, {Ham Min} and Kuo, {Meng Fai} and Tu, {Yong Kwang}",
year = "2009",
month = "6",
day = "15",
doi = "10.1002/ijc.24303",
language = "English",
volume = "124",
pages = "2872--2879",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors

AU - Kuo, Lu Ting

AU - Kuo, Kuang Ting

AU - Lee, Ming Jang

AU - Wei, Chih Chun

AU - Scaravilli, Francesco

AU - Tsai, Jui Chang

AU - Tseng, Ham Min

AU - Kuo, Meng Fai

AU - Tu, Yong Kwang

PY - 2009/6/15

Y1 - 2009/6/15

N2 - Recent studies have revealed a correlation between specific genetic changes, such as loss of chromosome 1p and 19q, and sensitivity of oligodendroglial neoplasm to radiotherapy and chemotherapy; epigenetic changes also play an important role in some tumors. In this retrospective study, we analyzed chromosomal alterations in 17 loci and promoter methylation status of 8 tumor-related genes in 49 oligodendroglial tumors (29 WHO grade II and 11 WHO grade III oligodendrogliomas; 7 WHO grade II and 2 WHO grade III oligoastrocytomas) using quantitative microsatellite analysis and methylation-specific polymerase chain reaction and correlated this information with clinical data. We also performed immunohistochemical stains for Ki-67 and O (6)-methyl guanine-DNA methyl transferase. Our results showed that the frequency of deletions in regions on 1p, 9p, 10q, 17p and 19q were 71.4%, 26.5%, 6.1%, 69.4% and 89.8%, respectively. Promoter methylation was detected in p14, p15, p16, p53, p73, PTEN, MGMT and RASSF1A genes in 24.5%, 6.1%, 46.9%, 0%, 6.1%, 42.9%, 53.1% and 77.6% of tumors, respectively. Statistical analysis identified that 9p22 loss, p73 methylation and p15 methylation were independently associated with reduced overall survival, and Ki-67 labeling index (LI) ≥ 5%, 9p22 loss, no loss of 19q, p73 methylation, p14 methylation and unmethylated MGMT predicted shorter progression-free survival. Our findings suggest that the frequent deletion and hypermethylation of tumor-related genes may represent a mechanism of tumor development and progression and emphasize the importance of defining new molecular markers for predicting prognosis, tumor recurrence and therapeutic response in cancer management.

AB - Recent studies have revealed a correlation between specific genetic changes, such as loss of chromosome 1p and 19q, and sensitivity of oligodendroglial neoplasm to radiotherapy and chemotherapy; epigenetic changes also play an important role in some tumors. In this retrospective study, we analyzed chromosomal alterations in 17 loci and promoter methylation status of 8 tumor-related genes in 49 oligodendroglial tumors (29 WHO grade II and 11 WHO grade III oligodendrogliomas; 7 WHO grade II and 2 WHO grade III oligoastrocytomas) using quantitative microsatellite analysis and methylation-specific polymerase chain reaction and correlated this information with clinical data. We also performed immunohistochemical stains for Ki-67 and O (6)-methyl guanine-DNA methyl transferase. Our results showed that the frequency of deletions in regions on 1p, 9p, 10q, 17p and 19q were 71.4%, 26.5%, 6.1%, 69.4% and 89.8%, respectively. Promoter methylation was detected in p14, p15, p16, p53, p73, PTEN, MGMT and RASSF1A genes in 24.5%, 6.1%, 46.9%, 0%, 6.1%, 42.9%, 53.1% and 77.6% of tumors, respectively. Statistical analysis identified that 9p22 loss, p73 methylation and p15 methylation were independently associated with reduced overall survival, and Ki-67 labeling index (LI) ≥ 5%, 9p22 loss, no loss of 19q, p73 methylation, p14 methylation and unmethylated MGMT predicted shorter progression-free survival. Our findings suggest that the frequent deletion and hypermethylation of tumor-related genes may represent a mechanism of tumor development and progression and emphasize the importance of defining new molecular markers for predicting prognosis, tumor recurrence and therapeutic response in cancer management.

KW - Epigenetic

KW - Genetic

KW - Glioma

KW - Oligodendroglial tumors

UR - http://www.scopus.com/inward/record.url?scp=65649087830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649087830&partnerID=8YFLogxK

U2 - 10.1002/ijc.24303

DO - 10.1002/ijc.24303

M3 - Article

VL - 124

SP - 2872

EP - 2879

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -